Cargando…

Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries

Formulation development was performed with the live, attenuated, human neonatal rotavirus vaccine candidate (RV3-BB) with three main objectives to facilitate use in low- and middle- income countries including (1) a liquid, 2–8°C stable vaccine, (2) no necessity for pre-neutralization of gastric acid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Prashant, Shukla, Ravi S., Patel, Ashaben, Pullagurla, Swathi R., Bird, Christopher, Ogun, Oluwadara, Kumru, Ozan S., Hamidi, Ahd, Hoeksema, Femke, Yallop, Christopher, Bines, Julie E., Joshi, Sangeeta B., Volkin, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189091/ https://www.ncbi.nlm.nih.gov/pubmed/33861183 http://dx.doi.org/10.1080/21645515.2021.1885279

Ejemplares similares

Effect of Formulation Variables on the Stability of a Live, Rotavirus (RV3-BB) Vaccine Candidate using in vitro Gastric Digestion Models to Mimic Oral Delivery
por: Kumar, Prashant, et al.
Publicado: (2021)

Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine
por: Hamidi, Ahd, et al.
Publicado: (2021)

Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine
por: Cowley, Daniel, et al.
Publicado: (2018)

Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth
por: Bines, Julie E., et al.
Publicado: (2018)

Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia
por: Cowley, Daniel, et al.
Publicado: (2018)

Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule
por: Geard, Nicholas, et al.
Publicado: (2022)

Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status
por: Boniface, Karen, et al.
Publicado: (2020)

Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the Nanopatch(TM) Microneedle Delivery System
por: Wan, Ying, et al.
Publicado: (2021)

Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB)
por: Cowley, Daniel, et al.
Publicado: (2019)

Rotaviruses and Rotavirus Vaccines
por: Donato, Celeste M., et al.
Publicado: (2021)

Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication
por: Kumar, Prashant, et al.
Publicado: (2022)

Crystallization of a nonreplicating rotavirus vaccine candidate
por: Hong, Moo Sun, et al.
Publicado: (2021)

Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate
por: Kumar, Prashant, et al.
Publicado: (2023)

Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study
por: Witte, Desiree, et al.
Publicado: (2022)

Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency
por: McAdams, David, et al.
Publicado: (2022)

Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies
por: Patel, Ashaben, et al.
Publicado: (2018)

Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration
por: Hu, Yue, et al.
Publicado: (2020)

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines
por: Kumru, Ozan S., et al.
Publicado: (2023)

Investigating barriers to the protective efficacy provided by rotavirus vaccines in African infants
por: Bines, Julie E.
Publicado: (2021)

Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018(TM) Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen
por: Bajoria, Sakshi, et al.
Publicado: (2023)

The Rv3799–Rv3807 gene cluster in Mycobacterium tuberculosis genome corresponds to the ‘Ancient Conserved Region’ in CMN mycolyltransferases
por: Ramulu, Hemalatha G., et al.
Publicado: (2007)

Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens
por: Agarwal, Sanjeev, et al.
Publicado: (2019)

Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine
por: Agarwal, Sanjeev, et al.
Publicado: (2020)

Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens
por: Agarwal, Sanjeev, et al.
Publicado: (2020)

Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine
por: Kumru, Ozan S., et al.
Publicado: (2019)

Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array
por: Wan, Ying, et al.
Publicado: (2018)

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)
por: Itzler, Robbin, et al.
Publicado: (2010)

Evaluation of Rv0220, Rv2958c, Rv2994 and Rv3347c of Mycobacterium tuberculosis for serodiagnosis of tuberculosis
por: You, Xiaolong, et al.
Publicado: (2017)

Holistic process development to mitigate proteolysis of a subunit rotavirus vaccine candidate produced in Pichia pastoris by means of an acid pH pulse during fed‐batch fermentation
por: Velez‐Suberbie, M. Lourdes, et al.
Publicado: (2020)

Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
por: Bajoria, Sakshi, et al.
Publicado: (2022)

Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia
por: Donato, Celeste M, et al.
Publicado: (2020)

Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine
por: Kaur, Kawaljit, et al.
Publicado: (2021)

Antibody response against koala retrovirus (KoRV) in koalas harboring KoRV-A in the presence or absence of KoRV-B
por: Olagoke, O., et al.
Publicado: (2019)

Investigation of the Rv3065, Rv2942, Rv1258c, Rv1410c, and Rv2459 efflux pump genes expression among multidrug-resistant Mycobacterium tuberculosis clinical isolates
por: Shahi, Fatemeh, et al.
Publicado: (2021)

Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years
por: Troeger, Christopher, et al.
Publicado: (2018)

Investigation of a monoclonal antibody against enterotoxigenic Escherichia coli, expressed as secretory IgA1 and IgA2 in plants
por: Teh, Audrey Y-H, et al.
Publicado: (2021)

Optimizing RV lead position in RV cardiomyopathy: Are we there yet?
por: Sharma, Apurva, et al.
Publicado: (2019)

Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus
por: Dalvie, Neil C., et al.
Publicado: (2021)

Rv2031c of Mycobacterium tuberculosis: a master regulator of Rv2028–Rv2031 (HspX) operon
por: Mushtaq, Khurram, et al.
Publicado: (2015)

The best of B.B. King
por: King, B. B.
Publicado: (1983)

Cannot write session to /tmp/vufind_sessions/sess_8iso2trqauijubkfmi3j8r3b8d